Navigation Links
Comparison of venlafaxine and SSRIs in the treatment of depression
Date:2/21/2008

Philadelphia, PA, February 21, 2008 There are numerous antidepressant medications currently on the market, but sadly, many patients still experience the debilitating symptoms of depression even with treatment. A new study published in the February 15th issue of Biological Psychiatry set out to compare two popular classes of antidepressants, the newer serotonin and norepinephrine reuptake inhibitors (SNRIs), like venlafaxine (Effexor), and the older selective serotonin reuptake inhibitors (SSRIs), like fluoxetine (Prozac) and citalopram (Celexa), to determine if one provides an overall greater benefit.

To do so, the authors performed a meta-analysis, by pooling the results of 34 double-blind randomized controlled trials that compared a single SNRI, venlafaxine, to other SSRIs. Dr. Charles Nemeroff, senior author on the paper, reports their findings: Venlafaxine was superior to SSRIs in efficacy overall, and moreover, statistically superior to fluoxetine but not to paroxetine, sertraline or citalopram. Venlafaxine had a higher dropout rate due to adverse events. These findings indicated a 5.9% advantage in remission rates for venlafaxine. The authors also report that the typical doctor would need to treat 17 patients to have a single patient benefit from being treated with venlafaxine rather than an SSRI.

Acknowledging the seemingly small advantage, John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, comments that this article highlights an advance that may have more importance for public health than for individual doctors and patients. He explains this reasoning:

If the average doctor was actively treating 200 symptomatic depressed patients and switched all of them to venlafaxine from SSRI, only 12 patients would be predicted to benefit from the switch. This signal of benefit might be very hard for that doctor to detect. But imagine that the entire population of depressed patients in the United States, estimated to be 7.1% of the population or over 21 million people, received a treatment that was 5.9% more effective, then it is conceivable that more than 1 million people would respond to venlafaxine who would not have responded to an SSRI. This may be an example of where optimal use of existing medications may improve public health even when it might not make much difference for individual doctors and patients.

Thus, in the typical clinical practice this difference constitutes a barely detectable benefit, but this difference could be meaningful across the large population of depressed patients in the United States.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Comparison of obstetric outcomes between on-call and patients own obstetricians
2. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
3. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
4. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
5. Diuretics excel in drug comparison trial involving hypertension/metabolic syndrome
6. Venlafaxine extended-release effective for patients with major depression
7. New treatment effective in counteracting cocaine-induced symptoms
8. New treatment boosts muscle function in myasthenia gravis
9. Broad-based group of physicians calls for improvement in stroke treatment
10. Cranberry Could Juice Up Ovarian Cancer Treatment
11. Non-medicinal treatment touted for pre-schoolers with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to ... Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed a ... or restricted lighting. As such, it eliminates the need to turn on a light ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
Breaking Medicine Technology: